Skip to main content

GSK vs Sanofi: Revenue, Profit and Business Model

GSK had ~$43.1B of annual revenue in FY2025 and ~$7.5B of net income. Sanofi had ~$49.3B of annual revenue in FY2025 and ~$8.8B of net income.

Latest financial snapshot

GSK

Latest annual revenue
~$43.1B (FY2025)
Net income
~$7.5B
Net margin
17.5%
Revenue growth
+1.8% a year, FY2016–FY2025

Sanofi

Latest annual revenue
~$49.3B (FY2025)
Net income
~$8.8B
Net margin
17.9%
Revenue growth
+2.7% a year, FY2021–FY2025

Financial summary

GSK

GSK reported 2025 turnover of ~$43.2 billion (£32.7 billion) (+4% at actual rates, +7% at constant currency), operating profit of ~$10.4 billion (£7.9 billion), profit attributable to shareholders of ~$7.52 billion (£5.7 billion), and earnings per share of 141.1p. Cash generated from operations was ~$11.7 billion (£8.9 billion) and free cash flow ~$5.28 billion (£4.0 billion). In Q2 2026, sales rose 5% to ~$11.1 billion (£8.4 billion) and core operating profit rose 7% to ~$3.7 billion (£2.8 billion), beating consensus, while reported operating profit fell to ~$635 million (£481 million) because of the camlipixant impairment. H1 2026 turnover was ~$21.1 billion (£16.0 billion). GSK reaffirmed 2026 guidance of 3% to 5% turnover growth and 7% to 9% core operating profit growth, expects a 70p dividend for 2026, and launched a three-year plan targeting ~$2.51 billion (£1.9 billion) of annual savings by 2029. GSK plc is a colossal British multinational pharmaceutical and biotechnology company, commanding a market valuation typically exceeding $70 billion.

Sanofi

Sanofi's finances now hinge on Dupixent. Sales of the antibody reached ~$17.7 billion (EUR15.7 billion) in 2025 and ~$5.88 billion (EUR5.2 billion) in Q2 2026 alone, up 37.6%, and management has targeted around $24.9 billion (EUR22 billion) by 2030. Group net sales grew from ~$46.4 billion (EUR41.081 billion) in 2024 to ~$49.3 billion (EUR43.626 billion) in 2025, free cash flow was about $9.15 billion (EUR8.1 billion), and Q2 2026 business EPS rose 33.3% at CER to EUR2.09. The 2025 Opella deal turned the consumer business into a 48.2% equity stake and brought in cash that Sanofi used for acquisitions such as Blueprint Medicines and share buybacks. Sanofi is a colossal French multinational pharmaceutical and healthcare company, commanding a massive market valuation generally exceeding $130 billion.

Revenue and profit by year

GSK

GSK revenue, net income, margin and growth by fiscal year
YearRevenueNet incomeMarginGrowthSource
FY2025~$43.1B~$7.5B17.5%+4.1%Source
FY2024~$41.4B~$3.4B8.2%+3.5%Source
FY2023~$40B~$6.5B16.2%+3.4%Source
FY2022~$38.7B~$19.7B51.0%+18.7%Source
FY2021~$32.6B~$5.8B17.8%+1.4%Source
FY2020~$32.1B~$7.6B23.6%-27.8%Source
FY2019~$44.6B~$6.1B13.8%+9.5%Source
FY2018~$40.7B~$4.8B11.8%+2.1%Source
FY2017~$39.8B~$2B5.1%+8.2%Source
FY2016~$36.8B~$1.2B3.3%—Source
Full GSK financials

Sanofi

Sanofi revenue, net income, margin and growth by fiscal year
YearRevenueNet incomeMarginGrowthSource
FY2025~$49.3B~$8.8B17.9%+6.2%Source
FY2024~$46.4B~$6.3B13.5%+8.6%Source
FY2023~$42.7B~$6.1B14.3%-6.2%Source
FY2022~$45.5B~$9.5B20.8%+2.9%Source
FY2021~$44.3B~$7B15.9%—Source
Full Sanofi financials

Where the revenue comes from

GSK

  • Specialty Medicines~41%

    Specialty Medicines generated ~$17.8 billion (GBP 13.5 billion) in FY2025 sales, led by HIV, respiratory, immunology and inflammation, and oncology assets.

  • Vaccines~28%

    Vaccines generated ~$12.1 billion (GBP 9.2 billion) in FY2025 sales, including Shingrix, meningitis vaccines, Arexvy, and other infectious-disease products.

  • General Medicines~31%

    General Medicines generated ~$13.2 billion (GBP 10.0 billion) in FY2025 sales, with established respiratory, anti-infective, and other medicines providing cash flow and scale.

Sanofi

  • Dupixent

    Not formally reported

    Antibody for atopic dermatitis, asthma, COPD and other type 2 diseases, shared with Regeneron; ~$17.7B (EUR15.7B) in 2025.

  • Vaccines

    Not formally reported

    Influenza, pediatric, meningitis, travel vaccines and Beyfortus; ~$8.93B (EUR7.9B) in 2025.

  • Pharma launches

    Not formally reported

    Newer medicines such as ALTUVIIIO, Ayvakit, Sarclisa and Tzield; ~$4.41B (EUR3.9B) in 2025.

  • Other medicines

    Not formally reported

    Established products including rare disease enzyme therapies, Toujeo, Lantus, Plavix and Lovenox; ~$18.2B (EUR16.1B) in 2025.

Business model and strategy

GSK

How it makes money

GSK makes money by discovering, manufacturing and selling prescription medicines and vaccines, mostly to health systems, insurers, pharmacies and governments. Its sales are reported in three groups.

Growth strategy

Under Luke Miels, GSK is combining targeted acquisitions with faster R&D. Deals since 2025 include IDRx (GIST, January 2025), efimosfermin from Boston Pharmaceuticals ($1.2 billion upfront, July 2025) and Nuvalent ($10.6 billion, completed July 2026).

Competitive advantage

GSK's advantages are scale in vaccine manufacturing, a long-acting HIV portfolio through ViiV Healthcare, and the AS01 adjuvant system used in Shingrix and Arexvy. Vaccines are hard to copy because they depend on biological manufacturing, cold-chain distribution and long-term government contracts.

GSK business model in full

Sanofi

How it makes money

Sanofi makes money by developing, manufacturing and selling prescription medicines and vaccines to hospitals, pharmacies, wholesalers, insurers and government health systems.

Growth strategy

Sanofi's strategy, set under Paul Hudson's 2019 'Play to Win' plan and now being tightened by Belén Garijo, is to concentrate on immunology, rare diseases, neurology and vaccines.

Competitive advantage

Sanofi's edge rests on two assets that are hard to copy. Dupixent is approved across a long list of type 2 inflammatory diseases, from atopic dermatitis and asthma to COPD and chronic spontaneous urticaria, which gives it unusual breadth for a single antibody.

Sanofi business model in full

Questions about GSK vs Sanofi

Which company has higher revenue — GSK plc or Sanofi S.A.?

GSK plc had ~$43.1B (FY2025), while Sanofi S.A. had ~$49.3B (FY2025). By latest annual revenue, Sanofi S.A. is the larger business, with GSK plc showing a smaller revenue base.

What is the market cap of GSK plc vs Sanofi S.A.?

GSK plc's market capitalisation stands at $100.0B, while Sanofi S.A.'s is $100.0B. GSK plc carries the higher market valuation, reflecting investors' expectations of its future earnings power relative to Sanofi S.A..

How does revenue per employee compare for GSK plc and Sanofi S.A.?

GSK plc has $646k / employee in revenue per employee, while Sanofi S.A. has $659k / employee. Headcounts may use different dates, so the ratio alone does not establish which business operates more efficiently.

How do GSK plc and Sanofi S.A. make money?

GSK plc and Sanofi S.A. generate revenue in fundamentally different ways. GSK plc: GSK makes money by discovering, manufacturing and selling prescription medicines and vaccines, mostly to health systems, insurers, pharmacies and governments. Sanofi S.A.: Sanofi makes money by developing, manufacturing and selling prescription medicines and vaccines to hospitals, pharmacies, wholesalers, insurers and government health systems.

Which company is valued higher relative to revenue — GSK plc or Sanofi S.A.?

On a price-to-sales (P/S) basis, GSK plc trades at 2.3x P/S and Sanofi S.A. at 2.0x P/S. GSK plc commands a higher revenue multiple, typically indicating that investors expect faster growth or higher future margins compared to Sanofi S.A.. A higher multiple is not inherently better — it may also signal that the stock is priced for perfection.

Is GSK plc bigger than Sanofi S.A.?

By last reported revenue, Sanofi S.A. (~$49.3B (FY2025)) is the larger company compared to GSK plc (~$43.1B (FY2025)). Revenue scale is one dimension of size — market capitalisation, employee count, and geographic reach are also relevant depending on the context.

Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the GSK vs Sanofi overview

Content is for informational purposes only. Not financial advice. Data sourced from SEC filings, annual reports, and public records. See our full disclaimer and methodology.